Pure Global AI
NCT06311864Not yet recruiting

Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada

PeriPharmClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Insomnia
Drug/Device/Intervention
Daridorexant 50 mg
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
PeriPharm
Location
Montreal, Canada
Timeline & enrollment
Phase
N/A
Start date
May 20, 2024
End date
Nov 01, 2024
Enrollment
100 participants
Primary outcome

Change from Baseline in Quality of Life,Change from Baseline in Work Productivity Loss,Change from Baseline in the Severity of Insomnia Symptoms

Summary

The purpose of this observational study is to evaluate the impact of daridorexant on quality
 of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia.

ICD-10 classifications
Nonorganic insomniaDisorders of initiating and maintaining sleep [insomnias]Sleep disordersSleep disorder, unspecifiedOther sleep disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06311864
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06311864 through Pure Global AI's free database. This phase not specified trial is sponsored by PeriPharm and is currently Not yet recruiting. The study focuses on Insomnia. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.